Aytu BioPharma (AYTU) Stock Price, News & Analysis

Company Overview

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Key Stats

• Today's Range: $1.20 to $1.31
• 50-Day Range: $1.00 to $1.35
• 52-Week Range: $0.95 to $3.45
• Volume: 13,156 shs
• Average Volume: 28,955 shs
• Market Capitalization: $7.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Aytu BioPharma Stock Analysis - MarketRank™

Aytu BioPharma scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Aytu BioPharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aytu BioPharma is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aytu BioPharma is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aytu BioPharma has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.98% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aytu BioPharma has recently increased by 1.19%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aytu BioPharma does not currently pay a dividend.

Dividend Growth

Aytu BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.45

Percentage of Shares Shorted

1.98% of the float of Aytu BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Aytu BioPharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aytu BioPharma has recently increased by 1.19%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Aytu BioPharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Aytu BioPharma is held by insiders.

Percentage Held by Institutions

Only 33.49% of the stock of Aytu BioPharma is held by institutions.

AYTU Stock Analysis - Frequently Asked Questions

How have AYTU shares performed this year?

Aytu BioPharma's stock was trading at $1.70 on January 1st, 2025. Since then, AYTU stock has decreased by 27.1% and is now trading at $1.24.
View the best growth stocks for 2025 here.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) posted its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.28) earnings per share for the quarter. Aytu BioPharma had a negative net margin of 7.62% and a negative trailing twelve-month return on equity of 19.30%.
Read the conference call transcript.

When did Aytu BioPharma's stock split?

Aytu BioPharma's stock reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE).

Company Calendar

• Last Earnings: 2/12/2025
• Today: 5/09/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AYTU
• CIK: 1385818
• Web: aytubio.com
• Phone: (720) 437-6580
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,840,000.00
• Net Margins: -7.62%
• Pretax Margin: -8.90%
• Return on Equity: -19.30%
• Return on Assets: -4.80%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 0.98
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: $77.23 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.64 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 6,170,000
• Free Float: 5,999,000
• Market Cap: $7.65 million
• Optionable: Not Optionable
• Beta: -0.10